Center for AIDS Research, University of Pennsylvania, Philadelphia, PA, USA.
Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA.
J Int AIDS Soc. 2010 Apr 20;13:15. doi: 10.1186/1758-2652-13-15.
The primary objective of this study was to determine the prevalence of neurocognitive impairment among HIV-positive individuals in Botswana, using the International HIV Dementia Scale (IHDS). We also compared performance on the IHDS with performance on tests of verbal learning/memory and processing speed, and investigated the association between performance on the IHDS and such variables as depression, age, level of education and CD4 count.
We conducted a cross-sectional study of 120 HIV-positive individuals randomly selected from an outpatient HIV clinic in Gaborone, Botswana. Patients provided a detailed clinical history and underwent neuropsychological testing; measures of depression, daily activities and subjective cognitive complaints were recorded.
Despite the fact that 97.5% of subjects were receiving highly active antiretroviral therapy (HAART), 38% met criteria for dementia on the IHDS, and 24% were diagnosed with major depressive disorder. There was a significant association between neurocognitive impairment as measured by the IHDS and performance on the other two cognitive measures of verbal learning/memory and processing speed. Level of education significantly affected performance on all three cognitive measures, and age affected processing speed and performance on the IHDS. Depression and current CD4 count did not affect performance on any of the cognitive measures.
The prevalence of neurocognitive impairment in HIV-positive individuals in Botswana is higher than expected, especially since almost all of the subjects in this study were prescribed HAART. This suggests the need to reconsider the timing of introduction of antiretroviral therapy in developing countries where HAART is generally not administered until the CD4 cell count has dropped to 200/mm3 or below. The contribution of other factors should also be considered, such as poor central nervous system penetration of some antiretrovirals, drug resistance, potential neurotoxicity, and co-morbidities. Memory impairment and poor judgment may be underlying causes for behaviours that contribute to the spread of HIV and to poor adherence. It is important to identify these neurobehavioural complications of HIV so that effective treatments can be developed.
本研究的主要目的是使用国际艾滋病毒痴呆量表(IHDS),确定博茨瓦纳艾滋病毒阳性个体的神经认知障碍患病率。我们还比较了 IHDS 与言语学习/记忆和处理速度测试的表现,并调查了 IHDS 表现与抑郁、年龄、教育程度和 CD4 计数等变量之间的关系。
我们对博茨瓦纳哈博罗内一家门诊艾滋病毒诊所的 120 名随机选择的艾滋病毒阳性个体进行了横断面研究。患者提供了详细的临床病史并接受了神经心理学测试;记录了抑郁、日常活动和主观认知抱怨的测量结果。
尽管 97.5%的受试者正在接受高效抗逆转录病毒治疗(HAART),但 38%的受试者符合 IHDS 的痴呆标准,24%的受试者被诊断为重度抑郁症。IHDS 测量的神经认知障碍与言语学习/记忆和处理速度的其他两项认知测试的表现之间存在显著关联。教育程度显著影响所有三项认知测试的表现,年龄影响处理速度和 IHDS 的表现。抑郁和当前 CD4 计数对任何认知测试的表现均无影响。
博茨瓦纳艾滋病毒阳性个体的神经认知障碍患病率高于预期,尤其是考虑到本研究中的几乎所有受试者都接受了 HAART 治疗。这表明需要重新考虑在发展中国家引入抗逆转录病毒治疗的时间,因为在 CD4 细胞计数降至 200/mm3 或以下之前,通常不会在这些国家使用 HAART。还应考虑其他因素的贡献,例如一些抗逆转录病毒药物对中枢神经系统的穿透率低、耐药性、潜在的神经毒性和合并症。记忆障碍和判断力差可能是导致 HIV 传播和治疗依从性差的行为的潜在原因。重要的是要识别出这些 HIV 的神经行为并发症,以便开发有效的治疗方法。